Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer.
Future Oncol
; 18(17): 2127-2139, 2022 Jun.
Article
em En
| MEDLINE
| ID: mdl-35414207
ABSTRACT
Aim:
To identify clinical and genetic variants associated with early-onset cardiac toxicity with a low cumulative dose of chemotherapy drugs in breast cancer.Methods:
A total of 388 recruited patients completed routine blood, liver and kidney function, D-dimer, troponin T, brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, ECG and echocardiography tests before and after adjuvant chemotherapy. 25 single-nucleotide polymorphisms (SNPs) were tested.Results:
A total of 277 adjuvant chemotherapy-related cardiac toxicity events were recorded in 180 patients (46.4%). Anthracycline-containing chemotherapy (odds ratio 1.848; 95% CI 1.135-3.008; p = 0.014) and the SLC28A3 rs885004 GG genotype (odds ratio 2.034; 95% CI 1.189-3.479; p = 0.010) were found to be associated with overall cardiac toxicity. The final predictive risk model consisting of clinical risk factors and SNPs was better than SNP alone (p = 0.006) or clinical risk factor alone (p = 0.065).Conclusion:
On the basis of clinical factors, a prediction model with genetic susceptibility factors can better predict early-onset cardiac toxicity.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Cardiotoxicidade
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China